Contemporary management of rectal cancer includes consideration of adjuvant anti EGFR therapy; however, KRAS mutational status profiling is mandatory prior to initiation of this therapy. KRAS mutational status is typically assayed on tissue samples (biopsy/surgical specimens). Radiomic features have demonstrated the ability to quantitatively characterize image phenotypic appearance associated with genotype expression in different tumors. We explored the utility of multi-scale, multi-oriented filter banks to define radiomics signatures that distinguish KRAS mutated vs wildtype tumors on T2W MRI. Initial results indicate that macro-scale radiomic features depict significantly different responses between the 2 genotypic groups.